New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 28, 2019 - Pfizer announced the FDA approval of Zirabev (bevacizumab-bvzr), a biosimilar to Genentech’s Avastin® (bevacizumab).
Download PDF
Return to publications
